Cytochrome P450 pharmacogenetics in African populations

Drug Metabolism Reviews

Volumn 45, Issue 2, 2013, Pages 253-275

  Alessandrini, Marco ^a   Asfaha, Sahle ^a   Dodgen, Tyren Mark ^a   Warnich, Louise ^b   Pepper, Michael Sean ^a,c  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

Bantu populations; CYP1; CYP2; CYP3; CYP450; Drug metabolism; Genotype phenotype relationship; Inter ethnic variability

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMFEBUTAMONE; AMITRIPTYLINE; AMODIAQUINE; ANTIDIABETIC AGENT; ANTIINFLAMMATORY AGENT; CLOZAPINE; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; EFAVIRENZ; LETROZOLE; NEVIRAPINE; PACLITAXEL; TEGAFUR; THEOPHYLLINE; WARFARIN; XENOBIOTIC AGENT;

AFRICA; ALLELE; DRUG METABOLISM; DRUG OXIDATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOME; GENOTYPE PHENOTYPE CORRELATION; PHARMACOGENETICS; REVIEW;

AFRICAN CONTINENTAL ANCESTRY GROUP; ALLELES; CYTOCHROME P-450 ENZYME SYSTEM; GENETIC VARIATION; GENOTYPE; HUMANS; PHARMACOGENETICS; PHENOTYPE;

EID: 84876570623     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.3109/03602532.2013.783062     Document Type: Review

References (208)

1. Abdel-Rahman SZ, Anwar WA, Abdel-Aal WE, et al. (1997). The CYP2D6 extensive metabolizer genotype is associated with increased risk for bladder cancer. Cancer Lett 119: 115-122. (Pubitemid 27464673)
2. Achour A, Zaag I, Gueddah L, et al. (2011). Role of CYP1A1 (T6235C) polymorphism and cigarette smoking in the development of coronary heart disease in Tunisian population. J Genet 90: 303-307.
3. Adjei GO, Kristensen K, Goka BQ, et al. (2008). Effect of concomitant artesunate administration and cytochrome P4502C8 polymorphisms on the pharmacokinetics of amodiaquine in Ghanaian children with uncomplicated malaria. Antimicrob Agents Chemother 52: 4400-4406.
4. Aklillu E, Carrillo JA, Makonnen E, et al. (2003). Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: Characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol Pharmacol 64: 659-669. (Pubitemid 37048569)
5. Aklillu E, Herrlin K, Gustafsson LL, et al. (2002). Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden. Pharmacogenetics 12: 375-383. (Pubitemid 34816417)
6. Aklillu E, Persson I, Bertilsson L, et al. (1996). Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 278: 441-446. (Pubitemid 27167124)
7. Allabi AC, Gala JL, Desager JP, et al. (2003). Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. Br J Clin Pharmacol 56: 653-657. (Pubitemid 37491717)
8. Allabi AC, Gala JL, Horsmans Y. (2005). CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet Genomics 15: 779-786. (Pubitemid 41531727)
9. Anwar WA, Abdel-Rahman SZ, EL-Zein RA, et al. (1996). Genetic polymorphism of GSTM1, CYP2E1 and CYP2D6 in Egyptian bladder cancer patients. Carcinogenesis 17: 1923-1929. (Pubitemid 26325384)
10. Babalola CP, Adejumo O, Ung D, et al. (2010). Cytochrome P450 CYP2C19 genotypes in Nigerian sickle-cell disease patients and normal controls. J Clin Pharm Ther 35: 471-477.
11. Bathum L, Skjelbo E, Mutabingwa TK, et al. (1999). Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population. Br J Clin Pharmacol 48: 395-401. (Pubitemid 29417724)
12. B'Chir F, Pavanello S, Knani J, et al. (2009). CYP1A2 genetic polymorphisms and adenocarcinoma lung cancer risk in the Tunisian population. Life Sci 84: 779-784.
13. Blaisdell J, Jorge-Nebert LF, Coulter S, et al. (2004). Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics 14: 527-537. (Pubitemid 39106854)
14. Blaisdell J, Mohrenweiser H, Jackson J, et al. (2002). Identification and functional characterization of new potentially defective alleles of human CYP2C19. Pharmacogenetics 12: 703-711. (Pubitemid 36054937)
15. Bolaji OO, Sadare IO, Babalola CP, Ogunbona FA. (2002). Polymorphic oxidative metabolism of proguanil in a Nigerian population. Eur J Clin Pharmacol 58: 543-545. (Pubitemid 35439155)
16. Bolt HM, Roos PH, Thier R. (2003). The cytochrome P-450 isoenzyme CYP2E1 in the biological processing of industrial chemicals: Consequences for occupational and environmental medicine. Int Arch Occup Environ Health 76: 174-185. (Pubitemid 36740737)
17. Bradford LD. (2002). CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3: 229-243. (Pubitemid 34223859)
18. Burk O, Tegude H, Koch I, et al. (2002). Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine. J Biol Chem 277: 24280-24288. (Pubitemid 34951946)
19. Cavaco I, Reis R, Gil JP, Ribeiro V. (2003). CYP3A4*1B and NAT2*14 alleles in a native African population. Clin Chem Lab Med 41: 606-609. (Pubitemid 36592130)
20. Cavaco I, Stromberg-Norklit J, Kaneko A, et al. (2005). CYP2C8 polymorphism frequencies among malaria patients in Zanzibar. Eur J Clin Pharmacol 61: 15-18. (Pubitemid 40558274)
21. Cavallari LH, Langaee TY, Momary KM, et al. (2010). Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin Pharmacol Ther 87: 459-464.
22. Chelule PK, Gordon M, Palanee T, et al. (2003). MDR1 and CYP3A4 polymorphisms among African, Indian, and white populations in KwaZulu-Natal, South Africa. Clin Pharmacol Ther 74: 195-196. (Pubitemid 36951818)
23. Chelule PK, Pegoraro RJ, Gqaleni N, Dutton MF. (2006). The frequency of cytochrome P450 2E1 polymorphisms in Black South Africans. Dis Markers 22: 351-354. (Pubitemid 46333634)
24. Cohen K, Grant A, Dandara C, et al. (2009). Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G4T polymorphism on efavirenz concentrations in adults in South Africa. Antivir Ther 14: 687-695.
25. Cote ML, Wenzlaff AS, Bock CH, et al. (2007). Combinations of cytochrome P-450 genotypes and risk of early-onset lung cancer in Caucasians and African Americans: A population-based study. Lung Cancer 55: 255-262. (Pubitemid 46329188)
26. Crews KR, Gaedigk A, Dunnenberger HM, et al. (2012). Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther 91: 321-326.
27. Csajka C, Marzolini C, Fattinger K, et al. (2003). Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther 73: 20-30. (Pubitemid 36158483)
28. Dai D, Zeldin DC, Blaisdell JA, et al. (2001). Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11: 597-607. (Pubitemid 32953585)
29. Dandara C, Ballo R, Parker MI. (2005). CYP3A5 genotypes and risk of oesophageal cancer in two South African populations. Cancer Lett 225: 275-282. (Pubitemid 40835875)
30. Dandara C, Basvi PT, Bapiro TE, et al. (2004). Frequency of-163 C4A and 63 C4G single nucleotide polymorphism of cytochrome P450 1A2 in two African populations. Clin Chem Lab Med 42: 939-941.
31. Dandara C, Lombard Z, DU Plooy I, et al. (2011). Genetic variants in CYP (-1A2,-2C9,-2C19,-3A4 and-3A5), VKORC1 and ABCB1 genes in a black South African population: A window into diversity. Pharmacogenomics 12: 1663-1670.
32. Dandara C, Masimirembwa CM, Magimba A, et al. (2001). Genetic polymorphism of CYP2D6 and CYP2C19 in east-And southern African populations including psychiatric patients. Eur J Clin Pharmacol 57: 11-17. (Pubitemid 32391406)
33. de Wit E, Delport W, Rugamika CE, et al. (2010). Genome-wide analysis of the structure of the South African Coloured Population in the Western Cape. Hum Genet 128: 145-153.
34. Dandara C, Sayi J, Masimirembwa CM, et al. (2002). Genetic polymorphism of cytochrome P450 1A1 (CYP1A1) and glutathione transferases (M1, T1 and P1) among Africans. Clin Chem Lab Med 40: 952-957. (Pubitemid 35277424)
35. Di Iulio J, Fayet A, Arab-Alameddine M, et al. (2009). In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet Genomics 19: 300-309.
36. Drogemoller BI, Wright GE, Niehaus DJ, et al. (2010). Characterization of the genetic profile of CYP2C19 in two South African populations. Pharmacogenomics 11: 1095-1103.
37. Droll K, Bruce-Mensah K, Otton SV, et al. (1998). Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians. Pharmacogenetics 8: 325-333. (Pubitemid 28372326)
38. Ebeshi BU, Bolaji OO, Masimirembwa C. (2011). Cytochrome P450 2D6 (CYP2D6) genotype and phenotype determination in the Nigerian population. Asian J Pharm Hea Sci 1: 47-54.
39. Edeki TI, Goldstein JA, DE Morais SM, et al. (1996). Genetic polymorphism of S-mephenytoin 40-hydroxylation in African-Americans. Pharmacogenetics 6: 357-360. (Pubitemid 26288626)
40. Elens L, Bouamar R, Hesselink DA, et al. (2011a). A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem 57: 1574-1583.
41. Elens L, Van Schaik RH, Panin N, et al. (2011b). Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics 12: 1383-1396.
42. Fernandez P, De Beer PM, Van Der Merwe L, Heyns CF. (2010). Genetic variations in androgen metabolism genes and associations with prostate cancer in South African men. S Afr Med J 100: 741-745.
43. Ferreira PE, Veiga MI, Cavaco I, et al. (2008). Polymorphism of antimalaria drug metabolizing, nuclear receptor, and drug transport genes among malaria patients in Zanzibar, East Africa. Ther Drug Monit 30: 10-15. (Pubitemid 351161093)
44. Fukami T, Nakajima M, Yoshida R, et al. (2004). A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo. Clin Pharmacol Ther 76: 519-527. (Pubitemid 39601542)
45. Gaedigk A, Bhathena A, Ndjountche L, et al. (2005). Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans. Pharmacogenomics J 5: 173-182. (Pubitemid 40852219)
46. Gaedigk A, Bradford LD, Marcucci KA, Leeder JS. (2002). Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin Pharmacol Ther 72: 76-89. (Pubitemid 34833189)
47. Gaedigk A, Coetsee C. (2008). The CYP2D6 gene locus in South African Coloureds: Unique allele distributions, novel alleles and gene arrangements. Eur J Clin Pharmacol 64: 465-475.
48. Gaedigk A, Ndjountche L, Gaedigk R, et al. (2003). Discovery of a novel nonfunctional cytochrome P450 2D6 allele, CYP2D642, in African American subjects. Clin Pharmacol Ther 73: 575-576. (Pubitemid 37249129)
49. Gaedigk A, Simon SD, Pearce RE, et al. (2008). The CYP2D6 activity score: Translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 83: 234-242.
50. Garcia-Martin E, Martinez C, Ladero JM, Agundez JA. (2006). Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol Diagn Ther 10: 29-40.
51. Garsa AA, McLeod HL, Marsh S. (2005). CYP3A4 and CYP3A5 genotyping by Pyrosequencing. BMC Med Genet 6: 19.
52. Garte S. (1998). The role of ethnicity in cancer susceptibility gene polymorphisms: The example of CYP1A1. Carcinogenesis 19: 1329-1332. (Pubitemid 28409826)
53. Garte S, Gaspari L, Alexandrie AK, et al. (2001). Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 10: 1239-1248. (Pubitemid 34027754)
54. Garte SJ, Trachman J, Crofts F, et al. (1996). Distribution of composite CYP1A1 genotypes in Africans, African-Americans and Caucasians. Hum Hered 46: 121-127. (Pubitemid 26110381)
55. Gellner K, Eiselt R, Hustert E, et al. (2001). Genomic organization of the human CYP3A locus: Identification of a new, inducible CYP3A gene. Pharmacogenetics 11: 111-121. (Pubitemid 32216122)
56. Gervasini G, Vizcaino S, Gasiba C, et al. (2005). Differences in CYP3A5*3 genotype distribution and combinations with other polymorphisms between Spaniards and Other Caucasian populations. Ther Drug Monit 27: 819-821. (Pubitemid 44391742)
57. Goldstein JA. (2001). Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 52: 349-355. (Pubitemid 32939439)
58. Gonzalez FJ, Gelboin HV. (1994). Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab Rev 26: 165-183. (Pubitemid 24171627)
59. Gounden V, Van Niekerk C, Snyman T, George JA. (2010). Presence of the CYP2B6 516G4 T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients. AIDS Res Ther 7: 32.
60. Griese EU, Asante-Poku S, Ofori-Adjei D, et al. (1999). Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population. Pharmacogenetics 9: 715-723. (Pubitemid 30011935)
61. Gross R, Aplenc R, Tenhave T, et al. (2008). Slow efavirenz metabolism genotype is common in Botswana. J Acquir Immune Defic Syndr 49: 336-337.
62. Guengerich FP, Hosea NA, Parikh A, et al. (1998). Twenty years of biochemistry of human P450s: Purification, expression, mechanism, and relevance to drugs. Drug Metab Dispos 26: 1175-1178. (Pubitemid 29028635)
63. Gunes A, Dahl ML. (2008). Variation in CYP1A2 activity and its clinical implications: Influence of environmental factors and genetic polymorphisms. Pharmacogenomics 9: 625-637. (Pubitemid 351803920)
64. Gyamfi MA, Fujieda M, Kiyotani K, et al. (2005). High prevalence of cytochrome P450 2A6*1A alleles in a black African population of Ghana. Eur J Clin Pharmacol 60: 855-857. (Pubitemid 40386155)
65. Haas DW, Bartlett JA, Andersen JW, et al. (2006). Pharmacogenetics of nevirapine-Associated hepatotoxicity: An Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis 43: 783-786. (Pubitemid 44330746)
66. Haas DW, Ribaudo HJ, Kim RB, et al. (2004). Pharmacogenetics of efavirenz and central nervous system side effects: An Adult AIDS Clinical Trials Group study. AIDS 18: 2391-2400. (Pubitemid 40065906)
67. Hamdy SI, Hiratsuka M, Narahara K, et al. (2002). Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br J Clin Pharmacol 53: 596-603. (Pubitemid 34621785)
68. Hamdy SI, Hiratsuka M, Narahara K, et al. (2003). Genotyping of four genetic polymorphisms in the CYP1A2 gene in the Egyptian population. Br J Clin Pharmacol 55: 321-324. (Pubitemid 36390765)
69. He P, Court MH, Greenblatt DJ, Von Moltke LL. (2005). Genotypephenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clin Pharmacol Ther 77: 373-387. (Pubitemid 40719266)
70. Herrlin K, Massele AY, Jande M, et al. (1998). Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. Clin Pharmacol Ther 64: 391-401. (Pubitemid 28473765)
71. Hu Y, Oscarson M, Johansson I, et al. (1997). Genetic polymorphism of human CYP2E1: Characterization of two variant alleles. Mol Pharmacol 51: 370-376. (Pubitemid 27118471)
72. Huang JD, Guo WC, Lai MD, et al. (1999). Detection of a novel cytochrome P-450 1A2 polymorphism (F21L) in Chinese. Drug Metab Dispos 27: 98-101.
73. Ikediobi O, Aouizerat B, Xiao Y, et al. (2011). Analysis of pharmacogenetic traits in two distinct South African populations. Hum Genomics 5: 265-282.
74. Ingelman-Sundberg M, Oscarson M, McLellan RA. (1999). Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment. Trends Pharmacol Sci 20: 342-349. (Pubitemid 29366813)
75. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. (2007). Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116: 496-526. (Pubitemid 350116943)
76. Inoue K, Asao T, Shimada T. (2000). Ethnic-related differences in the frequency distribution of genetic polymorphisms in the CYP1A1 and CYP1B1 genes in Japanese and Caucasian populations. Xenobiotica 30: 285-295. (Pubitemid 30179142)
77. Iyun AO, Lennard MS, Tucker GT, Woods HF. (1986). Metoprolol and debrisoquin metabolism in Nigerians: Lack of evidence for polymorphic oxidation. Clin Pharmacol Ther 40: 387-394. (Pubitemid 16009038)
78. Iyun AO, Tucker GT, Woods HF, Lennard MS. (1990). The 4-hydroxylation of S-mephenytoin in Nigerians: A population study. Br J Clin Pharmacol 30: 312P (abstract).
79. Jamshidi Y, Moreton M, Mckeown DA, et al. (2010). Tribal ethnicity and CYP2B6 genetics in Ugandan and Zimbabwean populations in the UK: Implications for efavirenz dosing in HIV infection. J Antimicrob Chemother 65: 2614-2619.
80. Jiang Z, Dalton TP, Jin L, et al. (2005). Toward the evaluation of function in genetic variability: Characterizing human SNP frequencies and establishing BAC-transgenic mice carrying the human CYP1A1-CYP1A2 locus. Hum Mutat 25: 196-206. (Pubitemid 40216616)
81. Johnson JA, Gong L, Whirl-Carrillo M, et al. (2011). Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther 90: 625-629.
82. Kato S, Shields PG, Caporaso NE, et al. (1992). Cytochrome P450IIE1 genetic polymorphisms, racial variation, and lung cancer risk. Cancer Res 52: 6712-6715.
83. Kisselev P, Schunck WH, Roots I, Schwarz D. (2005). Association of CYP1A1 polymorphisms with differential metabolic activation of 17beta-estradiol and estrone. Cancer Res 65: 2972-2978. (Pubitemid 40490103)
84. Kittles RA, Chen W, Panguluri RK, et al. (2002). CYP3A4-V and prostate cancer in African Americans: Causal or confounding association because of population stratification Hum Genet 110: 553-560. (Pubitemid 36075004)
85. Klein K, Lang T, Saussele T, et al. (2005). Genetic variability of CYP2B6 in populations of African and Asian origin: Allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics 15: 861-873. (Pubitemid 41666768)
86. Kudzi W, Dodoo AN, Mills JJ. (2009). Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population. BMC Med Genet 10: 124.
87. Kudzi W, Dodoo AN, Mills JJ. (2010). Genetic polymorphisms in MDR1, CYP3A4 and CYP3A5 genes in a Ghanaian population: A plausible explanation for altered metabolism of ivermectin in humans BMC Med Genet 11: 111.
88. Kuehl P, Zhang J, Lin Y, et al. (2001). Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27: 383-391. (Pubitemid 32268418)
89. Kwara A, Lartey M, Sagoe KW, et al. (2009). CYP2B6 (c.516G-4T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. Br J Clin Pharmacol 67: 427-436.
90. Lakhman SS, MA Q, Morse GD. (2009). Pharmacogenomics of CYP3A: Considerations for HIV treatment. Pharmacogenomics 10: 1323-1339.
91. Lamba JK, Lin YS, Thummel K, et al. (2002). Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 12: 121-132. (Pubitemid 34298916)
92. Leathart JB, London SJ, Steward A, et al. (1998). CYP2D6 phenotypegenotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics 8: 529-541. (Pubitemid 29043386)
93. Leeder JS, Gaedigk R, Marcucci KA, et al. (2005). Variability of CYP3A7 expression in human fetal liver. J Pharmacol Exp Ther 314: 626-635. (Pubitemid 41043843)
94. Lennard MS, Iyun AO, Jackson PR, et al. (1992). Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians. Pharmacogenetics 2: 89-92.
95. Li D, Dandara C, Parker MI. (2005). Association of cytochrome P450 2E1 genetic polymorphisms with squamous cell carcinoma of the oesophagus. Clin Chem Lab Med 43: 370-375. (Pubitemid 41460641)
96. Lim JS, Chen XA, Singh O, et al. (2011). Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. Br J Clin Pharmacol 71: 737-750.
97. Lim JS, Singh O, Ramasamy RD, et al. (2010). Pharmacogenetics of CYP1A2, novel polymorphisms and haplotypes in three distinct Asian populations. Drug Metab Pharmacokinet 25: 616-623.
98. Luo HR, Aloumanis V, Lin KM, et al. (2004). Polymorphisms of CYP2C19 and CYP2D6 in Israeli ethnic groups. Am J Pharmacogenomics 4: 395-401. (Pubitemid 40052848)
99. Maimbo M, Kiyotani K, Mushiroda T, et al. (2012). CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans. Eur J Clin Pharmacol 68: 267-271.
100. Marez D, Legrand M, Sabbagh N, et al. (1997). Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: Characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 7: 193-202. (Pubitemid 27290633)
101. Marsh S, King CR, Porche-Sorbet RM, et al. (2006). Population variation in VKORC1 haplotype structure. J Thromb Haemost 4: 473-474.
102. Masimirembwa CM, Beke M, Hasler JA, et al. (1995b). Low CYP1A2 activity in rural Shona children of Zimbabwe. Clin Pharmacol Ther 57: 25-31.
103. Masimirembwa C, Bertilsson L, Johansson I, et al. (1995a). Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. Clin Pharmacol Ther 57: 656-661.
104. Masimirembwa CM, Dandara C, Sommers DK, et al. (1998). Genetic polymorphism of cytochrome P4501A1, microsomal epoxide hydrolase, and glutathione S-transferases M1 and T1 in Zimbabweans and Venda of southern Africa. Pharmacogenetics 8: 83-85. (Pubitemid 28097605)
105. Masimirembwa CM, Gustafsson LL, Dahl ML, et al. (1996b). Lack of effect of chloroquine on the debrisoquine (CYP2D6 and S-mephenytoin (CYP2C19) hydroxylation phenotypes. Br J Clin Pharmacol 41: 344-346. (Pubitemid 26114822)
106. Masimirembwa CM, Hasler JA. (1997). Genetic polymorphism of drug metabolising enzymes in African populations: Implications for the use of neuroleptics and antidepressants. Brain Res Bull 44: 561-571. (Pubitemid 27494673)
107. Masimirembwa CM, Johansson I, Hasler JA, Ingelman-Sundberg M. (1993). Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population. Pharmacogenetics 3: 275-280. (Pubitemid 24061400)
108. Masimirembwa C, Persson I, Bertilsson L, et al. (1996a). A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: Association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol 42: 713-719. (Pubitemid 26417612)
109. Matimba A, Del-Favero J, Van Broeckhoven C, Masimirembwa C. (2009). Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects. Hum Genomics 3: 169-190.
110. Matimba A, Oluka MN, Ebeshi BU, et al. (2008). Establishment of a biobank and pharmacogenetics database of African populations. Eur J Hum Genet 16: 780-783. (Pubitemid 351865674)
111. Mbanefo C, Bababunmi EA, Mahgoub A, et al. (1980). A study of the debrisoquine hydroxylation polymorphism in a Nigerian population. Xenobiotica 10: 811-818. (Pubitemid 11203682)
112. Mberu EK,Wansor T, Sato HA, et al. (1995). Japanese poor metabolizers of proguanil do not have an increased risk of malaria chemoprophylaxis breakthrough. Trans R Soc Trop Med Hyg 89: 658-659.
113. Mcdonagh EM, Wassenaar C, David SP, et al. (2012). PharmGKB summary: Very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6. Pharmacogenet Genomics 22: 695-708.
114. Mehlotra RK, Bockarie MJ, Zimmerman PA. (2007). CYP2B6 983T4C polymorphism is prevalent in West Africa but absent in Papua New Guinea: Implications for HIV/AIDS treatment. Br J Clin Pharmacol 64: 391-395. (Pubitemid 47283857)
115. Mehlotra RK, Ziats MN, Bockarie MJ, Zimmerman PA. (2006). Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea. Eur J Clin Pharmacol 62: 267-275.
116. Mitchell C, Gregersen N, Krause A. (2011). Novel CYP2C9 and VKORC1 gene variants associated with warfarin dosage variability in the South African black population. Pharmacogenomics 12: 953-963.
117. Miura J, Obua C, Abbo C, et al. (2009). Cytochrome P450 2C19 genetic polymorphisms in Ugandans. Eur J Clin Pharmacol 65: 319-320.
118. Mizutani T. (2003). PM frequencies of major CYPs in Asians and Caucasians. Drug Metab Rev 35: 99-106. (Pubitemid 37048293)
119. Nakai K, Habano W, Nakai K, et al. (2005). Ethnic differences in CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu) genotypes in Japanese and Israeli populations. Life Sci 78: 107-111. (Pubitemid 41527238)
120. Nakajima M, Komagata S, Fujiki Y, et al. (2007). Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients. Pharmacogenet Genomics 17: 431-445. (Pubitemid 46763388)
121. Nakajima M, Yokoi T, Mizutani M, et al. (1994). Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: Absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiol Biomarkers Prev 3: 413-421. (Pubitemid 24221451)
122. Nakajima M, Yoshida R, Fukami T, et al. (2004). Novel human CYP2A6 alleles confound gene deletion analysis. FEBS Lett 569: 75-81. (Pubitemid 38844596)
123. Naoe T, Takeyama K, Yokozawa T, et al. (2000). Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/myelodysplastic syndrome and de novo acute myeloid leukemia. Clin Cancer Res 6: 4091-4095.
124. Nsabiyumva F, Furet Y, Autret E, et al. (1991). Oxidative polymorphism of dextromethorphan in a Burundi population. Eur J Clin Pharmacol 41: 75-77.
125. Nyakutira C, Roshammar D, Chigutsa E, et al. (2008). High prevalence of the CYP2B6 516G-4T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol 64: 357-365.
126. Oliveira E, Pereira R, Amorim A, et al. (2009). Patterns of pharmacogenetic diversity in African populations: Role of ancient and recent history. Pharmacogenomics 10: 1413-1422.
127. Ouerhani S, Marrakchi R, Bouhaha R, et al. (2008). The role of CYP2D6*4 variant in bladder cancer susceptibility in Tunisian patients. Bull Cancer 95: E1-E4.
128. Paganotti GM, Gallo BC, Verra F, et al. (2011). Human genetic variation is associated with Plasmodium falciparum drug resistance. J Infect Dis 204: 1772-1778.
129. Paganotti GM, Gramolelli S, Tabacchi F, et al. (2012). Distribution of human CYP2C8*2 allele in three different African populations. Malar J 11: 125.
130. Panserat S, Sica L, Gerard N, et al. (1999). CYP2D6 polymorphism in a Gabonese population: Contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype. Br J Clin Pharmacol 47: 121-124. (Pubitemid 29043175)
131. Parathyras J, Gebhardt S, Hillermann-Rebello R, et al. (2009). A pharmacogenetic study of CD4 recovery in response to HIV antiretroviral therapy in two South African population groups. J Hum Genet 54: 261-265.
132. Parikh S, Ouedraogo JB, Goldstein JA, et al. (2007). Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: Implications for malaria treatment in Africa. Clin Pharmacol Ther 82: 197-203. (Pubitemid 47075331)
133. Paris PL, Kupelian PA, Hall JM, et al. (1999). Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol Biomarkers Prev 8: 901-905. (Pubitemid 29508726)
134. Pavanello S, B'chir F, Pulliero A, et al. (2007). Interaction between CYP1A2-T2467DELT polymorphism and smoking in adenocarcinoma and squamous cell carcinoma of the lung. Lung Cancer 57: 266-272. (Pubitemid 47285430)
135. Penzak SR, Kabuye G, Mugyenyi P, et al. (2007). Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. HIV Med 8: 86-91. (Pubitemid 46390844)
136. Perera MA, Gamazon E, Cavallari LH, et al. (2011). The missing association: Sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans. Clin Pharmacol Ther 89: 408-415.
137. Persson I, Aklillu E, Rodrigues F, et al. (1996). S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. Pharmacogenetics 6: 521-526. (Pubitemid 27032304)
138. Phillips EJ, Mallal SA. (2008). Pharmacogenetics and the potential for the individualization of antiretroviral therapy. Curr Opin Infect Dis 21: 16-24.
139. Raimundo S, Toscano C, Klein K, et al. (2004). A novel intronic mutation, 2988G4A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. Clin Pharmacol Ther 76: 128-138. (Pubitemid 39013403)
140. Ribaudo HJ, Haas DW, Tierney C, et al. (2006). Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: An Adult AIDS Clinical Trials Group Study. Clin Infect Dis 42: 401-407. (Pubitemid 43122320)
141. Rodriguez-Antona C, Sayi JG, Gustafsson LL, et al. (2005). Phenotypegenotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. Biochem Biophys Res Commun 338: 299-305. (Pubitemid 41540570)
142. Rosemary J, Adithan C. (2007). The pharmacogenetics of CYP2C9 and CYP2C19: Ethnic variation and clinical significance. Curr Clin Pharmacol 2: 93-109. (Pubitemid 46729082)
143. Rotger M, Telenti A. (2008). Optimizing efavirenz treatment: CYP2B6 genotyping or therapeutic drug monitoring Eur J Clin Pharmacol 64: 335-336.
144. Rower S, Bienzle U, Weise A, et al. (2005). Short communication: High prevalence of the cytochrome P450 2C8*2 mutation in Northern Ghana. Trop
145. Roy JN, Lajoie J, Zijenah LS, et al. (2005). CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metab Dispos 33: 884-887. (Pubitemid 41002766)
146. Sachse C, Brockmöller J, Bauer S, Roots I. (1999). Functional significance of a C!A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 47: 445-449. (Pubitemid 29161279)
147. Santovito A, Burgarello C, Cervella P, Delpero M. (2010). Polymorphisms of cytochrome P450 1A1, glutathione s-transferases M1 and T1 genes in Ouangolodougou (Northern Ivory Coast). Genet Mol Biol 33: 434-437.
148. Schoch GA, Yano JK, Wester MR, et al. (2004). Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding site. J Biol Chem 279: 9497-9503. (Pubitemid 38296017)
149. Schoedel KA, Hoffmann EB, Rao Y, et al. (2004). Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 14: 615-626. (Pubitemid 39281816)
150. Scordo MG, Aklillu E, Yasar U, et al. (2001). Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol 52: 447-450. (Pubitemid 32939447)
151. Scott SA, Jaremko M, Lubitz SA, et al. (2009). CYP2C9*8 is prevalent among African-Americans: Implications for pharmacogenetic dosing. Pharmacogenomics 10: 1243-1255.
152. Scott SA, Sangkuhl K, Gardner EE, et al. (2011). Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther 90: 328-332.
153. Shastry BS. (2006). Pharmacogenetics and the concept of individualized medicine. Pharmacogenomics J 6: 16-21. (Pubitemid 43118306)
154. Shimada T, Yamazaki H, Mimura M, et al. (1994). Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270: 414-423. (Pubitemid 24229655)
155. Shrif NE, Won HH, Lee ST, et al. (2011). Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients. Eur J Clin Pharmacol 67: 1119-1130.
156. Sibbing D, Koch W, Gebhard D, et al. (2010a). Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 121: 512-518.
157. Sibbing D, Steinhubl SR, Schulz S, et al. (2010b). Platelet aggregation and its association with stent thrombosis and bleeding in clopidogreltreated patients: Initial evidence of a therapeutic window. J Am Coll Cardiol 56: 317-318.
158. Sim SC, Risinger C, Dahl ML, et al. (2006). A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79: 103-113. (Pubitemid 43069582)
159. Simooya OO, Njunju E, Hodjegan AR, et al. (1993). Debrisoquine and metoprolol oxidation in Zambians: A population study. Pharmacogenetics 3: 205-208. (Pubitemid 23265488)
160. Simooya OO, Sijumbil G, Lennard MS, Tucker GT. (1998). Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians. Br J Clin Pharmacol 45: 315-317. (Pubitemid 28081929)
161. Sirugo G, Hennig BJ, Adeyemo AA, et al. (2008). Genetic studies of African populations: An overview on disease susceptibility and response to vaccines and therapeutics. Hum Genet 123: 557-598.
162. Sistonen J, Fuselli S, Palo JU, et al. (2009). Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogenet Genomics 19: 170-179.
163. Sistonen J, Sajantila A, Lao O, et al. (2007). CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics 17: 93-101.
164. Skjelbo E, Mutabingwa TK, Bygbjerg I, et al. (1996). Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S-mephenytoin oxidation in Tanzanians. Clin Pharmacol Ther 59: 304-311. (Pubitemid 26117662)
165. Solus JF, Arietta BJ, Harris JR, et al. (2004). Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics 5: 895-931. (Pubitemid 39386756)
166. Sommers DK, Moncrieff J, Avenant J. (1988). Polymorphism of the 4-hydroxylation of debrisoquine in the San Bushmen of southern Africa. Hum Toxicol 7: 273-276.
167. Sommers DK, Moncrieff J, Avenant J. (1989a). Metoprolol alphahydroxylation polymorphism in the San Bushmen of southern Africa. Hum Toxicol 8: 39-43. (Pubitemid 19091212)
168. Sommers DK, Moncrieff J, Avenant J. (1989b). Non-correlation between debrisoquine and metoprolol polymorphisms in the Venda. Hum Toxicol 8: 365-368. (Pubitemid 19231633)
169. Sommers DK, Moncrieff J, Avenant J. (1990). Polymorphism in sparteine oxidation in the Barakwena (Kwengo) of Southern Africa. South Afr J Sci 86: 28-29.
170. Sommers DK, Moncrieff J, Avenant JC. (1991). Absence of polymorphism of sparteine oxidation in the South African Venda. Hum Exp Toxicol 10: 175-178.
171. Suarez-Kurtz G. (2011). Linkage disequilibrium between the CYP2C19*17 and CYP2C8*2 alleles in populations of African descent. Eur J Clin Pharmacol 67: 211-212.
172. Swart M, Skelton M, Wonkam A, et al. (2012). CYP1A2, CYP2A6, CYP2B6, CYP3A4 and CYP3A5 polymorphisms in two Bantuspeakiing populations from Cameroon and South Africa: Implications for global pharmacogenetics. Curr Pharmacogen Pers Med 10: 43-53.
173. Tang YM, Green BL, Chen GF, et al. (2000). Human CYP1B1 Leu432Val gene polymorphism: Ethnic distribution in African-Americans, Caucasians and Chinese; oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls. Pharmacogenetics 10: 761-766. (Pubitemid 32042828)
174. Tang YM, Wo YY, Stewart J, et al. (1996). Isolation and characterization of the human cytochrome P450 CYP1B1 gene. J Biol Chem 271: 28324-28330. (Pubitemid 26374648)
175. Tayeb MT, Clark C, Ameyaw MM, et al. (2000). CYP3A4 promoter variant in Saudi, Ghanaian and Scottish Caucasian populations. Pharmacogenetics 10: 753-756.
176. Telenti A, Zanger UM. (2008). Pharmacogenetics of anti-HIV drugs. Annu Rev Pharmacol Toxicol 48: 227-256. (Pubitemid 351738153)
177. Thompson EE, Kuttab-Boulos H, Witonsky D, et al. (2004). CYP3A variation and the evolution of salt-sensitivity variants. Am J Hum Genet 75: 1059-1069. (Pubitemid 39534403)
178. Tishkoff SA, Kidd KK, et al. (2004). Implications of biogeography of human populations for race and medicine. Nat Genet 36: S21-S27. (Pubitemid 41103834)
179. Tishkoff SA, Reed FA, Friedlaender FR, et al. (2009). The genetic structure and history of Africans and African Americans. Science 324: 1035-1044.
180. Tishkoff SA, Verrelli BC. (2003a). Patterns of human genetic diversity: Implications for human evolutionary history and disease. Annu Rev Genomics Hum Genet 4: 293-340. (Pubitemid 37392927)
181. Tishkoff SA, Verrelli BC. (2003b). Role of evolutionary history on haplotype block structure in the human genome: Implications for disease mapping. Curr Opin Genet Dev 13: 569-575. (Pubitemid 37456873)
182. Tishkoff SA, Williams SM. (2002). Genetic analysis of African populations: Human evolution and complex disease. Nat Rev Genet 3: 611-621. (Pubitemid 34827135)
183. Tsuchiya K, Gatanaga H, Tachikawa N, et al. (2004). Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun 319: 1322-1326. (Pubitemid 38759555)
184. Tyndale RF, Droll KP, Sellers EM. (1997). Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. Pharmacogenetics 7: 375-379. (Pubitemid 27427547)
185. Vasiliou V, Gonzalez FJ. (2008). Role of CYP1B1 in glaucoma. Annu Rev Pharmacol Toxicol 48: 333-358. (Pubitemid 351738157)
186. Walker AH, Jaffe JM, Gunasegaram S, et al. (1998). Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: Ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Online. Hum Mutat 12: 289 (abstract).
187. Wan YJ, Poland RE, Han G, et al. (2001). Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in southern California. Pharmacogenetics 11: 489-499. (Pubitemid 32778227)
188. Wandel C, Witte JS, Hall JM, et al. (2000). CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A4*1B50-promoter region polymorphism. Clin Pharmacol Ther 68: 82-91. (Pubitemid 30609830)
189. Wang D, Guo Y, Wrighton SA, et al. (2011). Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J 11: 274-286.
190. Wang XL, Raveendran M, Wang J. (2003). Genetic influence on cigarette-induced cardiovascular disease. Prog Cardiovasc Dis 45: 361-382. (Pubitemid 36403109)
191. Wang J, Sonnerborg A, Rane A, et al. (2006). Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genomics 16: 191-198.
192. Watkins PB. (1990). Role of cytochromes P450 in drug metabolism and hepatotoxicity. Semin Liver Dis 10: 235-250.
193. Weinshilboum R. (2003). Inheritance and drug response. N Engl J Med 348: 529-537. (Pubitemid 36159889)
194. Wennerholm A, Johansson I, Hidestrand M, et al. (2001). Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity. Pharmacogenetics 11: 417-427. (Pubitemid 32656582)
195. Wennerholm A, Johansson I, Massele AY, et al. (1999). Decreased capacity for debrisoquine metabolism among black Tanzanians: Analyses of the CYP2D6 genotype and phenotype. Pharmacogenetics 9: 707-714. (Pubitemid 30011934)
196. Wojnowski L, Turner PC, Pedersen B, et al. (2004). Increased levels of aflatoxin-Albumin adducts are associated with CYP3A5 polymorphisms in The Gambia, West Africa. Pharmacogenetics 14: 691-700. (Pubitemid 39411269)
197. Woolhouse NM, Andoh B, Mahgoub A, et al. (1979). Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians. Clin Pharmacol Ther 26: 584-591. (Pubitemid 10179573)
198. Woolhouse NM, Eichelbaum M, Oates NS, et al. (1985). Dissociation of co-regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians. Clin Pharmacol Ther 37: 512-521. (Pubitemid 15007277)
199. Wright GE, Niehaus DJ, Drogemoller BI, et al. (2010). Elucidation of CYP2D6 genetic diversity in a unique African population: Implications for the future application of pharmacogenetics in the Xhosa population. Ann Hum Genet 74: 340-350.
200. Xie HJ, Yasar U, Lundgren S, et al. (2003). Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J 3: 53-61. (Pubitemid 36432466)
201. Yasar U, Aklillu E, Canaparo R, et al. (2002). Analysis of CYP2C9*5 in Caucasian, Oriental and black-African populations. Eur J Clin Pharmacol 58: 555-558. (Pubitemid 35435508)
202. Yen-Revollo JL, Van Booven DJ, Peters EJ, et al. (2009). Influence of ethnicity on pharmacogenetic variation in the Ghanaian population. Pharmacogenomics J 9: 373-379.
203. Zanger UM, Raimundo S, Eichelbaum M. (2004). Cytochrome P450 2D6: Overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 369: 23-37. (Pubitemid 38161221)
204. Zeigler-Johnson CM, Walker AH, Mancke B, et al. (2002). Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4. Hum Hered 54: 13-21. (Pubitemid 35404245)
205. Zhou K, Donnelly L, Burch L, et al. (2010a). Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: A Go-DARTS study. Clin Pharmacol Ther 87: 52-56.
206. Zhou SF. (2009). Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part II. Clin Pharmacokinet 48: 761-804.
207. Zhou SF, Liu JP, Chowbay B. (2009). Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 41: 89-295.
208. Zhou SF, Zhou ZW, Huang M. (2010b). Polymorphisms of human cytochrome P450 2C9 and the functional relevance. Toxicology 278: 165-188.